MediPharm Labs Corp (MEDIF)

[DS CPA]

12m warrants hardly moved QoQ, those are not being dumped. I regularly track all dilutive and anti-dilutive equity components. Further, they disclosed that the O/S at 3/30/20 (per MD&A) is 134m which is only 3m higher than 12/31/19.

Lower revenue... for one quarter. And it still is higher than Q2 revenues (marginally).

Nasdaq $3 minimum bid requirement is well-known; their answer was only an update for those unaware.

No new deals? That’s just future revenue, so you are basically counting revenue performance twice. Who would be expecting contract announcements in this business environment? The hope is for ANY growth or protection of current business in a macro environment such as this.

I appreciate the response and I’m not trying to be argumentative, but it’s not quite registering with me. Would be curious to hear more about that other venture you brought up though, I am not aware.